Quanterix (QTRX) Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Does the media prefer PACB or QTRX?

In the previous week, Pacific Biosciences of California had 13 more articles in the media than Quanterix. MarketBeat recorded 27 mentions for Pacific Biosciences of California and 14 mentions for Quanterix. Quanterix's average media sentiment score of 0.67 beat Pacific Biosciences of California's score of 0.19 indicating that Quanterix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	5 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quanterix	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in PACB or QTRX?

86.5% of Quanterix shares are held by institutional investors. 2.4% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 6.9% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is PACB or QTRX more profitable?

Quanterix has a net margin of -30.71% compared to Pacific Biosciences of California's net margin of -227.69%. Quanterix's return on equity of -11.52% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-227.69%	-39.90%	-14.93%
Quanterix	-30.71%	-11.52%	-9.47%

Which has more risk & volatility, PACB or QTRX?

Pacific Biosciences of California has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Do analysts rate PACB or QTRX?

Pacific Biosciences of California currently has a consensus target price of $3.63, indicating a potential upside of 83.08%. Quanterix has a consensus target price of $23.25, indicating a potential upside of 87.50%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	0 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.47
Quanterix	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the MarketBeat Community favor PACB or QTRX?

Pacific Biosciences of California received 181 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 66.96% of users gave Pacific Biosciences of California an outperform vote while only 61.56% of users gave Quanterix an outperform vote.

Company	Underperform	Outperform
Pacific Biosciences of California	Outperform Votes 450 66.96%	Underperform Votes 222 33.04%
Quanterix	Outperform Votes 269 61.56%	Underperform Votes 168 38.44%

Which has better earnings & valuation, PACB or QTRX?

Quanterix has lower revenue, but higher earnings than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$200.52M	2.69	-$306.73M	-$1.46	-1.36
Quanterix	$127.95M	3.72	-$32.33M	-$1.05	-11.81

Summary

Quanterix beats Pacific Biosciences of California on 11 of the 18 factors compared between the two stocks.